Acute and sustained release of atrial natriuretic factor with acute myocardial infarction.
The present investigation was designed to determine if acute ischemic cardiac injury causes the release of atrial natriuretic factor (ANF). Seventeen patients with acute myocardial infarction but without clinical evidence of congestive heart failure had their circulating concentration of ANF and creatine phosphokinase monitored daily for 14 days. All 17 patients had an elevated plasma ANF concentration at time of presentation. Maximal increase in ANF was on day 2 and 3 post-infarction. This maximal increase correlated with the size of infarction estimated by the maximal creatine phosphokinase concentration (r = 0.475; p less than 0.05), but did not correlate with the amount of left ventricular dysfunction. ANF began to decrease by day 4 post-infarction and was normal at 10 days post-infarction in 14 of the 17 (82%) patients. At 12 days post-infarction, all 17 patients had normal ANF levels. Another three patients with acute myocardial infarction were treated with tissue plasminogen activator (tPA). The measured ANF levels in these patients were within our normal range and were significantly lower (p less than 0.001) than those seen in patients with acute myocardial infarction not given thrombolytic therapy. Six patients with unstable angina likewise had normal circulating ANF concentrations during prolonged episodes of chest pain. These levels were also significantly lower (p less than 0.001) than the 17 patients with acute infarcts not given tPA. The distinct pattern of release of ANF may be useful as an adjunct to serum cardiac enzymes in determining if a myocardial infarction has occurred.
Ngo
L
L
Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock 72205-7199.
Vesely
D L
DL
Bissett
J K
JK
Murphy
M L
ML
Dinh
H
H
Seth
R
R
Sallman
A L
AL
Rico
D M
DM
Winters
C J
CJ
Wyeth
R P
RP
D000328:Adult; D000368:Aged; D000789:Angina, Unstable / Q000378:metabolism; D009320:Atrial Natriuretic Factor / Q000097:blood*; D003402:Creatine Kinase / Q000097:blood; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy / Q000201:enzymology; D012016:Reference Values; D013997:Time Factors
D005343:Fibrinolytic Agents; D009320:Atrial Natriuretic Factor; D003402:Creatine Kinase